CD274 and hepatocellular carcinoma: Furthermore, TANs have been shown to induce impaired antitumor immunity via the modulation of PD-L1/PD-1 signaling pathway, influencing the efficacy of PD-1 therapy in hepatocellular carcinoma (HCC) [154].